207 related articles for article (PubMed ID: 35751378)
1. Contribution of haemodynamic side effects and associated autonomic reflexes to ventricular arrhythmias triggering by torsadogenic hERG blocking drugs.
Champéroux P; Fares R; Bastogne T; Richard S; Le Guennec JY; Thireau J
Br J Pharmacol; 2022 Sep; 179(18):4549-4562. PubMed ID: 35751378
[TBL] [Abstract][Full Text] [Related]
2. The high frequency relationship: implications for torsadogenic hERG blockers.
Champeroux P; Le Guennec JY; Jude S; Laigot C; Maurin A; Sola ML; Fowler JS; Richard S; Thireau J
Br J Pharmacol; 2016 Feb; 173(3):601-12. PubMed ID: 26589499
[TBL] [Abstract][Full Text] [Related]
3. Short-term variability in QT interval and ventricular arrhythmias induced by dofetilide are dependent on high-frequency autonomic oscillations.
Champeroux P; Thireau J; Judé S; Laigot-Barbé C; Maurin A; Sola ML; Fowler JS; Richard S; Le Guennec JY
Br J Pharmacol; 2015 Jun; 172(11):2878-91. PubMed ID: 25625756
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Katchman AN; Koerner J; Tosaka T; Woosley RL; Ebert SN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1098-106. PubMed ID: 16278312
[TBL] [Abstract][Full Text] [Related]
5. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
6. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
7. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.
Testai L; Bianucci AM; Massarelli I; Breschi MC; Martinotti E; Calderone V
Curr Med Chem; 2004 Oct; 11(20):2691-706. PubMed ID: 15544470
[TBL] [Abstract][Full Text] [Related]
8. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.
Schneider J; Hauser R; Andreas JO; Linz K; Jahnel U
Eur J Pharmacol; 2005 Apr; 512(1):53-60. PubMed ID: 15814090
[TBL] [Abstract][Full Text] [Related]
11. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
12. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
[TBL] [Abstract][Full Text] [Related]
13. QT alterations in psychopharmacology: proven candidates and suspects.
Alvarez PA; Pahissa J
Curr Drug Saf; 2010 Jan; 5(1):97-104. PubMed ID: 20210726
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
Vicente J; Johannesen L; Mason JW; Crumb WJ; Pueyo E; Stockbridge N; Strauss DG
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25870186
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
17. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
18. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
19. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]